Anthony Bergmann Sells 25,000 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $31.70, for a total value of $792,500.00. Following the sale, the chief financial officer owned 8,223 shares in the company, valued at $260,669.10. The trade was a 75.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Anthony Bergmann also recently made the following trade(s):

• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Stock Down 1.6%

Shares of CAPR opened at $32.96 on Wednesday. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37. The firm has a market capitalization of $1.91 billion, a PE ratio of -14.58 and a beta of 0.48. The stock’s fifty day simple moving average is $31.20 and its 200-day simple moving average is $22.94.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). Analysts anticipate that Capricor Therapeutics, Inc. will post 0.01 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on CAPR. Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a report on Tuesday, March 10th. B. Riley Financial boosted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a report on Friday, March 13th. Cantor Fitzgerald set a $62.00 price target on Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. Finally, Wall Street Zen lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Capricor Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $46.09.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in Capricor Therapeutics by 12.4% during the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares during the period. ACT Capital Management LLC bought a new position in Capricor Therapeutics during the fourth quarter worth about $43,000. Nuveen LLC grew its holdings in Capricor Therapeutics by 2.1% during the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after purchasing an additional 1,878 shares during the period. State of Wyoming grew its holdings in Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 1,913 shares during the period. Finally, GoalVest Advisory LLC acquired a new stake in Capricor Therapeutics during the fourth quarter worth approximately $59,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.